This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes (TNDM) Gains on Pump Sales, Margin Woe Stays
by Zacks Equity Research
Tandem Diabetes (TNDM) is now increasing its renewal numbers both in volume and rates.
Why Is Masimo (MASI) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2
by Zacks Equity Research
Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.
Tandem Diabetes (TNDM) Q4 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 50% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Tops Q3 Earnings Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 11.90% and 5.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Tandem (TNDM) to Expand Global Insulin Pump Base With New Buy
by Zacks Equity Research
The AMF Medical acquisition will help Tandem (TNDM) advance with its sustainability objectives by offering an additional pump that minimizes electronic and battery waste generation.
Tandem Diabetes (TNDM) Q3 Earnings Miss, Sales View Cut
by Zacks Equity Research
Tandem Diabetes (TNDM) defers $0.6 million of United States pump sales as a result of Tandem Choice.
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -800% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include Tandem Diabetes Care, Krispy Kreme, Caesars Entertainment and Vestas Wind Systems
by Zacks Equity Research
Tandem Diabetes Care, Krispy Kreme, Caesars Entertainment and Vestas Wind Systems are part of Zacks Screen of the week article.
RxSight, Inc. (RXST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
RxSight, Inc. (RXST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Get Rid of Your Stress by Dumping These 4 Toxic Stocks
by Rimmi Singhi
Detoxify your portfolio by selling stocks like Tandem Diabetes (TNDM) Krispy Kreme (DNUT), Caesars Entertainment (CZR) and Vestas Wind (VWDRY).
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q3 Earnings Expected to Decline
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Toxic Stocks That May Stress You Out Amid Market Turmoil
by Rimmi Singhi
Just like identifying promising stocks, detecting toxic stocks and dumping them at the right time are crucial to safeguarding one's portfolio from big losses.
Zacks.com featured highlights InnovAge Holding, Spirit AeroSystems Holdings, Tandem Diabetes Care and HCI Group
by Zacks Equity Research
InnovAge Holding, Spirit AeroSystems Holdings, Tandem Diabetes Care and HCI Group have been highlighted in this Screen of The Week article.
4 Toxic Stocks That May Risk Your Peace and Prosperity
by Rimmi Singhi
Stocks like INVV, SPR, TNDM and HCI could prove hazardous for your portfolio. So, it's best to dump these toxic stocks, especially amid the prevailing market mayhem.
Tandem Diabetes (TNDM) Faces Expense Woes, Macro Issues
by Zacks Equity Research
Factoring in the pandemic and competitive pressure as well as evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) slashes full-year guidance.
Distance Yourself From These 4 Toxic Stocks to Ward Off Losses
by Rimmi Singhi
It's time to cut ties with toxic stocks including CNK, LVS, TNDM and HCI to safeguard your portfolio.
Zacks.com featured highlights include Heska, Tandem Diabetes Care, Credit Suisse Group, Zalando SE and Las Vegas Sands
by Zacks Equity Research
Heska, Tandem Diabetes Care, Credit Suisse Group, Zalando SE and Las Vegas Sands are part of Zacks Screen of the Week article.
5 Toxic Stocks That May Prove Hazardous for Your Portfolio
by Rimmi Singhi
Toxic companies are characterized by huge debt pile and are vulnerable to external shocks. Accurately identifying such stocks and getting rid of them at the right time can protect your portfolio. CS, LVS, HSKA, TNDM and ZLNDY are five such stocks.
Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut
by Zacks Equity Research
Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.
Implied Volatility Surging for Tandem Diabetes Care (TNDM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Tandem Diabetes Care (TNDM) stock based on the movements in the options market lately.
Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes
by Zacks Equity Research
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.
CVRx (CVRX) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.